Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: jopawa who wrote (788)	12/17/1998 2:28:00 PM
From: jopawa	Read Replies (1) \| Respond to of 2539

Thursday December 17, 11:46 am Eastern Time Company Press Release SOURCE: Searle Kaken Pharmaceutical Co. and Searle Enter into License Agreement For Arthrotec(R) in the Japanese Market SKOKIE, Ill., Dec. 17 /PRNewswire/ -- Kaken Pharmaceutical Co., Ltd. and Searle, the pharmaceutical sector of Monsanto Company (NYSE:MCT - news; NYSE: MTC - news), announced today that they have entered into an agreement whereby Searle will license Japanese rights to its pharmaceutical product Arthrotec® for the treatment of the pain and inflammation of arthritis. Financial terms were not disclosed. ''This agreement will ensure that we expand our activities in Japan,'' said Mr. Yoshiharu Wakiyama, President of Kaken Pharmaceutical Co., Ltd. ''We look forward to this new collaboration with Searle.'' ''This transaction further enhances our relationship with Kaken,'' said Bruce R. Sents, President, Asia Pacific World Area for Searle. Kaken is a Tokyo-based pharmaceutical company that develops and markets human and animal pharmaceuticals, and agricultural and chemical products. Searle, the pharmaceutical sector of Monsanto Company, researches and develops pharmaceutical products and healthcare solutions worldwide. SOURCE: Searle